Elina Lavit joined OncoNano in May 2022 to drive strategic partnerships and business development activities to support the company’s continued growth. Mrs. Lavit brings over 18 years of experience in leadership roles in organizations ranging from start-ups to Fortune 100 corporations in various therapeutic areas, including oncology and surgery.
Mrs. Lavit previously served as Executive Director, Program Management at Taysha Gene Therapies, where she led alliance management, strategy, and execution for one of the company’s leading assets. Previously, she served as Director of Program Management at Myokardia (acquired by BMS) providing strategic program management support for a first-in-class drug candidate. Mrs. Lavit gained significant strategic collaboration experience while working at Pharmacyclics, AbbVie, and Ethicon (a subsidiary of Johnson & Johnson).
Mrs. Lavit earned her Bachelor of Science in Economics and Biology and Master of Science in Medical Science from Tel Aviv University.